Antonello Veccia
Overview
Explore the profile of Antonello Veccia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veccia A, Dipasquale M, Lorenzi M, Monteverdi S, Kinspergher S, Zambotti E, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002263
The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction of EGFR tyrosine kinase inhibitors in clinical practice, both in advanced...
2.
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis D, et al.
Lung Cancer
. 2024 Dec;
199:108059.
PMID: 39700681
Background: As for squamous (Sq)-NSCLC, Checkmate-017 trial showed a significant overall survival (OS) improvement in favor of Nivolumab (Nivo) over Docetaxel in 2nd-line. We hypothesized that anticipating Nivo use, as...
3.
Caffo O, Basso U, Cattrini C, Ermacora P, Maruzzo M, Alberti M, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102265.
PMID: 39662149
Introduction: Over the years, several prognostic models were developed in patients receiving chemotherapy for metastatic castration resistant prostate cancer (mCRPC), while data on androgen-receptor signaling inhibitors (ARSI) in a real-world...
4.
Veccia A, Dipasquale M, Kinspergher S, Caffo O
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594826
Introduction: In recent years, several inflammation-related factors and nutritional parameters have been evaluated to develop prognostic scores as potential biomarkers in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors...
5.
Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione I, Menis J, et al.
Front Oncol
. 2024 Jul;
14:1436588.
PMID: 39045557
Introduction: To date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to test for driver alterations to identify actionable therapeutic targets. In this light, comprehensive genomic profiling...
6.
7.
Casagrande S, Sopetto G, Bertalot G, Bortolotti R, Racanelli V, Caffo O, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611115
The landscape of cancer treatment has undergone a significant transformation with the introduction of Immune Checkpoint Inhibitors (ICIs). Patients undergoing these treatments often report prolonged clinical and radiological responses, albeit...
8.
Inno A, Veccia A, Madonia G, Berti A, Bortolotti R, Incorvaia L, et al.
Front Cardiovasc Med
. 2024 Feb;
11:1309100.
PMID: 38370161
Introduction: Combinations of immune checkpoint inhibitors (ICIs) and angiogenesis inhibitors (AIs) have been investigated for the treatment of several tumor types. Both ICIs and AIs may lead to cardiovascular adverse...
9.
Celsa C, Cabibbo G, Fulgenzi C, Scheiner B, DAlessio A, Manfredi G, et al.
J Hepatol
. 2023 Nov;
80(3):431-442.
PMID: 37972660
Background & Aims: Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes...
10.
Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, et al.
iScience
. 2023 Oct;
26(11):107970.
PMID: 37860695
The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the...